Why was the UK puberty blockers trial paused?

Regulators stepped in after safety and design concerns

A high-profile clinical study examining puberty-blocking treatment for young people with gender incongruence has been paused by regulators. The decision followed formal concerns raised about the trial’s design and participant safeguards, including guidance that participants should be at least 14 years old. Regulators told the research team to halt recruitment and reconsider aspects of how the study selects and protects children taking part.

Alongside those scientific and ethical worries, the trial’s leadership came under scrutiny. A senior clinician reported to have influence over the study was removed from involvement after social media posts expressing gender-critical views prompted questions about potential bias. The regulator said that the investigator would no longer take part in the trial’s oversight while the pause is in effect.

Why this matters

Puberty-blocking medications are already used in some clinical settings, but high-quality trial evidence about long-term benefits and harms has been limited. Pausing the trial delays the production of rigorous data that could inform clinicians, families and policymakers about the balance of risks and benefits. At the same time, regulators and patient advocates have argued that participant safety, transparent governance and freedom from bias are prerequisites for ethically robust research on this sensitive topic.

What comes next

The research team will need to respond to regulator requests, revise protocols where required and resolve leadership concerns before recruitment can resume. Families and clinicians seeking clearer evidence will face a longer wait, and the episode has intensified public debate about how best to conduct research involving young people and gender-related care.